Clinical trials: Healthy Volunteers.
Type I Hypersensitivity
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated.
- Trial name
- NCT00109759
- Testing
- RagweedMATAMPL
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Healthy
A Study of Donanemab (LY3002813) in Healthy Participants
The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants.
- Trial name
- NCT05567159
- Testing
- Donanemab
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Healthy
A Study of LY3154207 on Sleep in Healthy Male Participants
This study will evaluate the effect of single doses of LY3154207 on the amount of time it takes for healthy sleep-deprived men to fall asleep.
- Trial name
- NCT02603861
- Testing
- LY3154207, Modafinil
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Insufficiency
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
- Trial name
- NCT01019070
- Testing
- BMS-650032
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus Infection
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
- Trial name
- NCT05141422
- Testing
- SHR2150 tablet、efavirenz
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteer
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
- Trial name
- NCT07378579
- Testing
- ESK-001, Moxifloxacin (400 mg)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Alumis Inc
Healthy
Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
The objectives of this study are: To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers To compare the pharmacokinetic…
- Trial name
- NCT01494727
- Testing
- CJ Amlodipine/Valsartan 10/160mg, Novartis Exforge 10/160mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A
The aim was to verify the Pharmacokinetics and Pharmacodynamics of alpha interferon product-2A - Blausiegel, taking as the comparator drug product Roferon ® A (interferon alpha-2A - Roche Laboratory).
- Trial name
- interferon (NCT01228422)
- Testing
- Interferon alpha 2a
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy
Bioequivalence Study of Lu AF35700
The purpose of this study is to establish bioequivalence of Lu AF35700 between the clinical formulation and the commercial formulation for three tablet strengths; 5, 10 and 20 mg
- Trial name
- NCT03394482
- Testing
- Lu AF35700 5 mg clinical formulation, Lu AF35700 5 mg commercial formulation, Lu AF35700 10 mg clinical formulation
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Autoimmune Disease
First in Human Study of ALT-01 in Healthy Participants
The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants
- Trial name
- NCT07865442
- Testing
- ALT-01
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Altis Medicines, Inc
Pharmacokinetics of ASP2408, Healthy Subjects
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of…
- Trial name
- NCT02150070
- Testing
- ASP2408
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is…
- Trial name
- NCT06662396
- Testing
- MK-6552, Diltiazem
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo
- Trial name
- NCT02262546
- Testing
- Pramipexole extended-release (ER) tablets, Pramipexole immediate-release (IR) tablets, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A Single and Multiple Ascending Dose Study of COR588
The study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects.
- Trial name
- NCT04920903
- Testing
- COR588
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Cortexyme Inc.
Idiopathic Pulmonary Fibrosis
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
- Trial name
- NCT05134727
- Testing
- AZD5055
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human…
- Trial name
- NCT05387083
- Testing
- Low Dose TP-05, High Dose TP-05
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
- Trial name
- NCT05804383
- Testing
- BMS-984923
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allyx Therapeutics
Healthy
A Study to Evaluate the Safety of K-755 in Healthy Volunteers
This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.
- Trial name
- NCT03414294
- Testing
- K-755 Part A (SAD), K-755 Part B (MAD), K-755 Part C (FE)
- Where
- Australia
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Kowa Company, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.